STCube to Participate in JP Morgan Healthcare Conference

STCube announced on December 15 that it will participate in the 'JP Morgan Healthcare Conference 2026,' which will be held in San Francisco, USA, from January 12 to 15 next year. The company plans to hold discussions regarding a global technology licensing-out (L/O) agreement for its BTN1A1-targeted immuno-oncology drug, Nelmastobart.

Jung Hyunjin, CEO of STCube, stated, "JP Morgan will serve as an opportunity to move beyond exploratory discussions about Nelmastobart and to discuss business structure and development strategy on the premise of actual adoption." He added, "Nelmastobart fully meets the requirements for continued global discussions, including its mechanism of action, clinical data, biomarker potential, and marketability."

He continued, "As interest in Nelmastobart's latest clinical results and BTN1A1 biomarker data grows, the weight of these discussions is changing significantly. We see 2026 as a crucial year for delivering tangible results."

STCube will hold several business meetings with global top-tier pharmaceutical companies. Since presenting at the Society for Immunotherapy of Cancer (SITC) in the United States last month, the company has increased its contacts with major corporations, resulting in the confirmation of numerous meetings.

According to the recently announced initial results of the phase 1b/2 clinical trial of Nelmastobart in combination with trifluridine/tipiracil and bevacizumab for metastatic colorectal cancer, all six patients in phase 1b showed tumor reduction responses. Two patients achieved partial response (PR). In addition, as of four months after administration, not a single case of disease progression (PD) was reported. In phase 2, cases of sustained tumor reduction and stable disease continue to be observed.

The biomarker potential of BTN1A1 is also a key factor driving global pharmaceutical companies' interest. As a longer duration of response has been observed in patients with high BTN1A1 expression, Nelmastobart's development competitiveness appears to be further strengthened.

Yoo Seunghan, Chief Scientific Officer (CSO) of STCube, said, "Nelmastobart has great potential to establish itself as a new immune axis that can overcome the limitations of existing immuno-oncology drugs. At this year's JP Morgan conference, we will continue discussions with global companies, focusing on the underlying mechanism and clinical data."

STCube expects to complete the enrollment of all patients in the phase 1b/2 trial for metastatic colorectal cancer within this year. Currently, the enrollment of 55 patients has been completed. In addition, for non-small cell lung cancer (NSCLC), the company has obtained IND approval for a phase 2 clinical trial combining Nelmastobart with docetaxel and is preparing for the first dose. The company expects that the combination therapy with Nelmastobart will have lower toxicity and a longer duration of response compared to existing treatments.